Cosciens Biopharma (CSCI) Q4 2024 earnings summary

Executive summary

• Repositioned as a pure-play natural-based product company after strategic review and pipeline prioritization.

• Streamlined operations and cost-cutting measures implemented; ended Q4 with $16.4M in cash.

• 2024 marked by merger completion, pipeline consolidation, and focus on advancing promising programs.

• Ceased investment in pre-clinical and macimorelin development after negative Phase 3 DETECT trial; exploring divestment options.

Financial highlights

• Full-year 2024 revenue was $9.6M, up 35.2% year-over-year from $7.1M in 2023.

• Q4 2024 revenue reached $3.3M, up from $1.2M in Q4 2023, driven by Avenanthramides, Beta Glucan, and Macrilen sales.

• Full-year net loss was $15.3M ($5.93/share) vs. $3.5M ($1.89/share) in 2023, mainly due to higher R&D, SG&A, and impairment expenses.

• Q4 net loss was $6.7M ($2.15/share) vs. $1.6M ($0.85/share) in Q4 2023.

• Cash and cash equivalents at year-end totaled $16.4M.

Outlook and guidance

• Focused on commercializing natural-based cosmeceutical, nutraceutical, and pharmaceutical products.

• Oat Beta Glucan chewable bar and Yeast Beta Glucan immune booster targeted for H2 2025 launches.

• Avenanthramide protein bar for exercise-induced inflammation planned for launch by year-end 2025.

• Advancing Avenanthramides tablets in Phase 2a clinical study.